# HALO Trial: Haloperidol vs Olanzapine in Hyperactive Delirium in Palliative Care Patients; A Multi-Centre, Randomised-Controlled Trial

> **NCT04833023** · PHASE3 · UNKNOWN · sponsor: **Tan Tock Seng Hospital** · enrollment: 72 (estimated)

## Conditions studied

- Haloperidol
- Advanced Cancer
- Hyperactive Delirium
- Olanzapine
- End-stage Organ Disease

## Interventions

- **DRUG:** Haldol 2mg/ml oral solution
- **DRUG:** Olanzapine Actavis 5mg orodispersible tablet

## Key facts

- **NCT ID:** NCT04833023
- **Lead sponsor:** Tan Tock Seng Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-05-18
- **Primary completion:** 2024-12
- **Final completion:** 2024-12
- **Target enrollment:** 72 (ESTIMATED)
- **Last updated:** 2024-04-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04833023

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04833023, "HALO Trial: Haloperidol vs Olanzapine in Hyperactive Delirium in Palliative Care Patients; A Multi-Centre, Randomised-Controlled Trial". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04833023. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*